Histogenics Corporation, a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced the appointment of Adam Gridley to President and Chief Executive Officer and as a member of the Company’s Board of Directors. Mr. Gridley brings over 20 years of proven results in the medical device and pharmaceutical industries, with a combination of transactional and public markets experience as well as strong operational leadership and product development expertise. Mr. Gridley’s career has focused on strategic elements of corporate growth with a demonstrated and successful track record in strategic planning, manufacturing and R&D expansions, and corporate and technology integrations.
Prior to joining Histogenics, Mr. Gridley most recently served as Senior Vice President, Technical Operations at Merz, a privately-held specialty healthcare company focused on the development and commercialization of products for aesthetics, dermatology and neurosciences, where he was a global site head responsible for manufacturing and quality operations, information technology and sourcing activities. Previously, Mr. Gridley was Senior Vice President of Corporate Development for BioForm Medical, Inc. a publically-traded company that was acquired by Merz in 2010. In this role, Mr. Gridley was responsible for all business development, investor relations, strategic planning, product development activities and R&D functions for the organization. Prior to that, Mr. Gridley held several key strategic leadership roles in the orthopedics space during his career including Director of Business Development and Investor Relations at Gliatech Inc. Mr. Gridley holds a Bachelor of Science and a Master of Business Administration from the University of Denver.
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Our regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Our first investigational product candidate, NeoCart®, leverages our platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee. For more information on Histogenics, please visit the company website at www.histogenics.com.